Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Comerica Bank

Comerica Bank lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 65.7% during the 4th quarter, HoldingsChannel.com reports. The fund owned 4,040 shares of the biopharmaceutical company’s stock after selling 7,750 shares during the quarter. Comerica Bank’s holdings in Alnylam Pharmaceuticals were worth $1,607,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sanctuary Advisors LLC lifted its position in Alnylam Pharmaceuticals by 5.6% during the 4th quarter. Sanctuary Advisors LLC now owns 6,520 shares of the biopharmaceutical company’s stock worth $2,593,000 after acquiring an additional 345 shares during the period. Munich Reinsurance Co Stock Corp in Munich acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $109,000. Concurrent Investment Advisors LLC acquired a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $319,000. Generali Investments Management Co LLC acquired a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $384,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Alnylam Pharmaceuticals by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 25,267 shares of the biopharmaceutical company’s stock worth $10,047,000 after purchasing an additional 2,480 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 2,242 shares of the firm’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $695,199.36. Following the transaction, the executive vice president owned 24,848 shares of the company’s stock, valued at approximately $7,704,867.84. This trade represents a 8.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 6,958 shares of the firm’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $2,157,536.64. Following the transaction, the chief executive officer directly owned 85,662 shares in the company, valued at approximately $26,562,072.96. This represents a 7.51% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 38,656 shares of company stock valued at $12,370,696. Corporate insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $295.91 on Friday. The firm has a market capitalization of $39.51 billion, a PE ratio of 80.85 and a beta of 0.31. The business’s fifty day moving average price is $318.15 and its 200 day moving average price is $372.43. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. Alnylam Pharmaceuticals, Inc. has a 12 month low of $245.96 and a 12 month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.Alnylam Pharmaceuticals’s revenue for the quarter was up 96.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.44) earnings per share. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.17 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on ALNY shares. Morgan Stanley cut their price objective on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research note on Friday, January 30th. Wells Fargo & Company upped their price target on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a research report on Friday, May 1st. Needham & Company LLC lowered their price objective on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Jefferies Financial Group reiterated a “hold” rating and issued a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Finally, Barclays began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $471.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.